6-bromo-3-(3-methoxy-propyl)-imidazo[1,2-a]pyrimidine | 865156-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-bromo-3-(3-methoxy-propyl)-imidazo[1,2-a]pyrimidine
• 英文别名: 6-Bromo-3-(3-methoxypropyl)imidazo[1,2-a]pyrimidine
• CAS: 865156-65-6
• 化学式: C₁₀H₁₂BrN₃O
• 分子量: 270.129
• InChiKey: JUDZLBDUYHIUJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION<br/>[FR] DERIVE DE 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE UTILISES EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090305A1

  公开（公告）日：2005-09-29

  The application relatés to novel alkanamides of the general formula (I) where X is -CH2- or >CH-OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl­C1-C6-alkyl; R5 is Cl-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy­ C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-Cl-C6-alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1,-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-Cl-C6-alkyl, optionally substituted aryl-­Co-C6-alkyl, optionally substituted C3-C8-cycloalkyl-Co-C6-alkyl or optionally substituted heterocydyl-Co-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  该申请涉及一般式（I）的新型烷酰胺，其中X为-CH2-或>CH-OH；（A）R1例如是一个可选择取代的杂环基团或一个可选择取代的多环不饱和碳氢基团，其中X为羟甲基；R2为C1-C6-烷基或C3-C6-环烷基；R3各自独立地为H、C1-C6-烷基、C1-6-烷氧羰基或C1-C6-烷酰基；R4为C1-C6-烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基-C1-C6-烷基；R5为Cl-C6-烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-烷酰氧基-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-Cl-C6-烷基、C1-C6-烷酰胺基-C1-C6-烷基、HO(O)C-C1-C6-烷基、C1-C6-烷基-O-(O)C-C1-C6-烷基、H2N-C(O)-C1-C6-烷基、C1-C6-烷基-HN-C(O)-C1-C6-烷基、（C1,-C6-烷基）2N-C(O)-C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代Cl-C6-烷基、可选择取代的芳基-Co-C6-烷基、可选择取代的C3-C8-环烷基-Co-C6-烷基或可选择取代的杂环基-Co-C6-烷基；以及它们的制备方法和将这些化合物用作药物的用途，特别是作为肾素抑制剂治疗高血压。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• Organic Compounds
  申请人：Herold Peter

  公开号：US20080058320A1

  公开（公告）日：2008-03-06

  The invention relates to novel amino alcohols of the general formula (I) where X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型的氨基醇，其通式为(I)，其中X，R1，R2，R3，R4，R5和R6分别如详细描述中所定义，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension
  申请人：Herold Peter

  公开号：US20080280895A1

  公开（公告）日：2008-11-13

  The application relates to novel alkanamides of the general formula (I) where X is —CH 2 — or >CH—OH; (A) R 1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R 2 is C 1 -C 6 -alkyl or C 3 -C 6 -cydoalkyl; R 3 are each independently H, C 1 -C 6 -alkyl, C 1-6 -alkoxycarbonyl or C 1 -C 6 -alkanoyl; R 4 is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -alkenyl or unsubstituted or substituted arylC 1 -C 6 -alkyl; R 5 is C 1 -C 6 -alkyl, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoyloxy C 1 -C 6 -alkyl, C 1 -C 6 -aminoalkyl, C 1 -C 6 -alkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -dialkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoylamido-C 1 -C 6 -alkyl, HO(O)C—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-O—(O)C—C 1 -C 6 -alkyl, H 2 N—C(O)—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-HN—C(O)—C 1 -C 6 -alkyl, (C 1 , —C 6 -alkyl) 2 N—C(O)—C 1 -C 6 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, cyano-C 1 -C 6 -alkyl, halo-C 1 -C 6 -alkyl, optionally substituted aryl-C o -C 6 -alkyl, optionally substituted C 3 -C 8 -cycloalkyl-C o -C 6 -alkyl or optionally substituted heterocydyl-C o -C 6 -alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  该申请涉及到通式（I）的新型烷基酰胺，其中X为—CH2—或>CH—OH；（A）R1为例如可选择取代的杂环基基团或可选择取代的多环不饱和碳氢基团，其中X为羟甲基；R2为C1-C6-烷基或C3-C6-环烷基；R3各自独立地为H、C1-C6-烷基、C1-6-烷氧羰基或C1-C6-酰基；R4为C1-C6-烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基C1-C6-烷基；R5为C1-C6-烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-酰氧-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-C1-C6-烷基、C1-C6-酰胺基-C1-C6-烷基、HO(O)C—C1-C6-烷基、C1-C6-烷基-O—(O)C—C1-C6-烷基、H2N—C(O)—C1-C6-烷基、C1-C6-烷基-HN—C(O)—C1-C6-烷基、（C1，—C6-烷基）2N—C(O)—C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代-C1-C6-烷基、可选择取代的芳基-Co-C6-烷基、可选择取代的C3-C8-环烷基-Co-C6-烷基或可选择取代的杂环基-Co-C6-烷基；以及它们的制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂治疗高血压。
• 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension
  申请人：HEROLD Peter

  公开号：US20100063087A1

  公开（公告）日：2010-03-11

  Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH 2 —; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R 2 is C 1-6 alkyl or C 3-6 cycloalkyl; R 3 is independently of one another H, C 1-6 alkyl, C 1-6 alkoxycarbonyl or C 1-6 alkanoyl; R 4 is C 2-6 alkenyl, C 1-6 alkyl, unsubstituted or substituted aryl-C 1-6 alkyl or C 3-8 cycloalkyl; R 5 is -L m -R ; L is C 1-6 alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R 6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy- C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=0: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=1: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 -alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension.

  通式（I）的化合物或其盐或其中一个或多个原子被其稳定的非放射性同位素替换的化合物，特别是其药学上可接受的盐；其中X为-CH2-；R为1至4个氮原子的单取代、双取代、三取代或四取代的单环或双环不饱和杂环基，R2为C1-6烷基或C3-6环烷基；R3独立地为H、C1-6烷基、C1-6烷氧羰基或C1-6酰基；R4为C2-6烯基、C1-6烷基、未取代或取代的芳基-C1-6烷基或C3-8环烷基；R5为-Lm-R；L为C1-6烷基，可选地被1-4个卤素取代，或为连接基：通式（II）n=0、1或2；m=0或1；R6为由自行选择的2个环系统组成的基，所述环系统选择自双环[x.y.z]烷基、螺[O.P]烷基、单环或双氧杂双环[x.y.z]烷基或单环或双氧杂螺[O.P]烷基，所有这些基都可以被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基，或如果m=0：还是饱和的C3-8杂环基，其中包括1-2个氧原子，被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基，或如果m=1：还是饱和的C3-8杂环基，其中包括1-2个氧原子，可选地被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基；具有抑制肾素的性质，可用作治疗高血压的药物。